Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature.

Autor: De Las Cuevas C; Department of Internal Medicine, Dermatology, and Psychiatry and Instituto Universitario de Neurociencia (IUNE), Universidad de La Laguna, La Laguna, Spain., de Leon VC; Department of Psychiatry, Washington University School of Medicine in St Louis, St Louis, MO, USA., Blasco-Fontecilla H; Instituto de Investigación, Transferencia e Innovación, Ciencias de la Saludy Escuela de Doctorado, Universidad Internacional de La Rioja, Logroño, Spain.; Emooti, Madrid, Spain.; Center of Biomedical Network Research on Mental Health (CIBERSAM), Carlos III Institute of Health, Madrid, Spain., Baca-García E; Center of Biomedical Network Research on Mental Health (CIBERSAM), Carlos III Institute of Health, Madrid, Spain.; Department of Psychiatry, Hospital Fundación Jiménez Díaz, Madrid, Spain.; Complutense University of Madrid, Madrid, Spain.; Universidad Católica del Maule, Talca, Chile.; Department of Psychiatry, Centre Hospitalier Universitaire de Nîmes, Nîmes, France., Sagud M; School of Medicine, University of Zagreb, Zagreb, Croatia.; University Hospital Centre Zagreb, Zagreb, Croatia., Sanz EJ; Department of Physical Medicine and Pharmacology, School of Medicine, Universidad de La Laguna, Spain.; Hospital Universitario de Canarias, Tenerife, Spain., de Leon J; Mental Health Research Center, Eastern State Hospital, Lexington, KY, USA.; Biomedical Research Centre in Mental Health Net (CIBERSAM), Santiago Apóstol Hospital, University of the Basque Country, Vitoria, Spain.
Jazyk: angličtina
Zdroj: Expert opinion on drug safety [Expert Opin Drug Saf] 2024 Sep 11, pp. 1-11. Date of Electronic Publication: 2024 Sep 11.
DOI: 10.1080/14740338.2024.2399094
Abstrakt: Background: In the United States, clozapine was first approved for treatment-resistant schizophrenia and then for suicidality in schizophrenia psychoses. Systematic reviews support clozapine's anti-suicidal effect, but the forensic literature stresses its lethality during overdoses.
Research Design and Methods: Clozapine reports to the international pharmacovigilance database (VigiBase) were analyzed for suicidal ideation, suicide attempts, intentional overdose, and completed suicides from introduction to 1 January 2024. VigiBase uses the information component (IC) as a disproportionality analysis.
Results: The clozapine ICs (range: other antipsychotics) were: 1) suicidal ideation IC = 0.570 with IC 025 = 0.454 to IC 975  = 0.680 (IC = 3.568 for aripiprazole and 1.729 for risperidone), 2) suicide attempt IC = 1.428 with IC 025 = 1.323 to IC 975  = 1.529 (IC = 4.150 for quetiapine and 2.968 for risperidone), 3) intentional overdose: IC = 0.995 with IC 025  = 0.864 to IC 975  = 1.120 (IC = 4.080 for quetiapine and 1.957 for aripiprazole), and 4) completed suicide IC = 1.133 with IC 025  = 1.026 to IC 975  = 1.235 (IC = 4.648 for quetiapine and 2.160 for risperidone). In summary, all clozapine ICs were significantly lower. We found 2391 clozapine-treated patients on the suicidality spectrum (627 cases with suicidal ideation, 752 with suicide attempt, 488 with intentional overdose, and 731 with completed suicide) but many were taking other antipsychotics. The most frequent reporting countries were the United States, the United Kingdom, and Croatia.
Conclusion: This pharmacovigilance study, with all its inherent limitations, provides independent proof, not overlapping with prior literature, that clozapine may have specific strong anti-suicidal effects that do not appear to be present in other antipsychotics. Further VigiBase studies are needed to compare the lethality of an intentional overdose of clozapine (14.3%) with other antipsychotics.
Databáze: MEDLINE
Externí odkaz: